Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 7/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TLR5 | O60602 | 3/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11884995 | 0.80 | LIMK1 (0.50) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL24270401 | 0.79 | LIMK1 (0.41) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL25463887 | 0.79 | CLK1 (0.38) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL20120213 | 0.78 | CDC7 (0.30) | CLK1LIMK1CDC7DBF4 | |
| SCHEMBL26423734 | 0.77 | CLK1 (0.40) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL26423737 | 0.77 | CLK1 (0.40) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL606019 | 0.77 | LIMK1 (0.50) | LIMK1PIK3CAEGFR | |
| SCHEMBL24270403 | 0.77 | LIMK1 (0.44) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL22483140 | 0.77 | LIMK1 (0.53) | CLK1LIMK1CDC7DBF4EGFR | |
| SCHEMBL5406439 | 0.75 | LMNA (0.42) | CLK1LIMK1CDC7DBF4TLR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207645-A1 | Pyridothienopyrimidine Derivatives | PAGES SANTACANA LUIS MIGUEL | 2008-08-28 | — | — | US | claimed |
| EP-1623987-A1 | Fused pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and pyrido[3',2':4,5]furo[3,2-d]pyrimidines | Curacyte Discovery GmbH (DE) | 2006-02-08 | — | — | EP | claimed |
| EP-1619196-A1 | Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and Pyrido[3',2':4,5]furo[3,2-d]-pyrimidines for use as inhibitors of PDA-4 and/or TNF-alpha release | Curacyte Discovery GmbH (DE) | 2006-01-25 | — | — | EP | claimed |
| US-12048237-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| US-11760769-B2 | Composition and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-09-19 | — | — | US | disclosed |
| US-11760769-B2 | Composition and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-09-19 | — | — | US | disclosed |
| EP-3558309-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230151020-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230151020-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20220223794-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND APPLICATION THEREOF | Wuhan Tianma Microelectronics Co., Ltd. Shanghai Branch (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-4002509-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2022-05-25 | — | — | EP | disclosed |
| WO-2006058723-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-08 | — | — | WO | disclosed |
| EP-1623987-A1 | Fused pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and pyrido[3',2':4,5]furo[3,2-d]pyrimidines | Curacyte Discovery GmbH (DE) | 2006-02-08 | — | — | EP | disclosed |
| EP-1623987-A1 | Fused pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and pyrido[3',2':4,5]furo[3,2-d]pyrimidines | Curacyte Discovery GmbH (DE) | 2006-02-08 | — | — | EP | disclosed |
| EP-1623987-A1 | Fused pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and pyrido[3',2':4,5]furo[3,2-d]pyrimidines | Curacyte Discovery GmbH (DE) | 2006-02-08 | — | — | EP | disclosed |
| WO-2006010567-A1 | SUBSTITUTED PYRIDO[3', 2': 4, 5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3', 2': 4, 5]FURO[3, 2, D]PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF$G(A) | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| EP-1619196-A1 | Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and Pyrido[3',2':4,5]furo[3,2-d]-pyrimidines for use as inhibitors of PDA-4 and/or TNF-alpha release | Curacyte Discovery GmbH (DE) | 2006-01-25 | — | — | EP | disclosed |
| EP-1619196-A1 | Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and Pyrido[3',2':4,5]furo[3,2-d]-pyrimidines for use as inhibitors of PDA-4 and/or TNF-alpha release | Curacyte Discovery GmbH (DE) | 2006-01-25 | — | — | EP | disclosed |
| EP-1619196-A1 | Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and Pyrido[3',2':4,5]furo[3,2-d]-pyrimidines for use as inhibitors of PDA-4 and/or TNF-alpha release | Curacyte Discovery GmbH (DE) | 2006-01-25 | — | — | EP | disclosed |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220223794-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND APPLICATION THEREOF | NR0B2, FPR3, NPR3 | CLK1 2296/4885LIMK1 3355/4885CDC7 1709/4885 |
| US-20050101601-A1 | Substituted tricyclic heterocycles and their uses | LTC4S, NQO1, CBR3 | CLK1 3223/4885LIMK1 4013/4885CDC7 1740/4885 |
| US-20080207645-A1 | Pyridothienopyrimidine Derivatives | PDE4A, PDE5A, PDE3B | CLK1 4338/4885LIMK1 4202/4885CDC7 3729/4885 |
| US-12048237-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, OSBP | CLK1 1076/4885LIMK1 1588/4885CDC7 3817/4885 |
| US-20230151020-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | OCIAD1, OCIAD2, EHD1 | CLK1 3888/4885LIMK1 351/4885CDC7 3272/4885 |
| US-11760769-B2 | Composition and organic light-emitting device including the same | CRY1, CRY2, LEF1 | CLK1 1991/4885LIMK1 84/4885CDC7 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.